Alli and Xenical (Orlistat) Could Cause Severe Liver Injury: FDA Warns of Dangers of Weight Loss Drug
Yet another weight loss drug has been accused of posing a safety risk due to its potential causing of liver damage or failure. Yesterday the U.S. Food and Drug Administration (FDA) completed its safety review of the the weight loss drug Orlistat, which has been marketed under the names of Alli and Xenical, in connection with reports of severe liver injury. Alli is manufactured by GlaxoSmithKline (GSK), while Xenical is manufactured by Hoffmann-La Roche (Roche).
These reports of potential liver damage due to a weight loss drug come on the heels of similar reports of liver injury associated with Hydroxycut, which led to a massive recall of the weight loss supplement.
After undergoing an investigation into the safety of Xenical and Alli, the FDA found that Alli and Xenical could in fact cause liver damage in rare cases and therefore has approved the weight loss drugs to stay on the market as long as their labels are changed to include warnings of potential liver damage.
According to a lawsuit that was filed in 2009 against the driver of a sport utility vehicle that collided with a station wagon that was driven by the boy’s father, the boy was a passenger in the front seat when it was struck by the northbound SUV attempting to turn east onto Old Orchard Road from Skokie Boulevard. This crash took place in front of the
The court upheld a Chicago, Cook County jury award of $6.35 million in compensatory damages after finding that the plaintiff established that taking wrong drug caused the decedent’s kidneys to fail, which led to his death. The plaintiff died during pretrial proceedings.
Perhaps even more alarming is that at least half of these dangerous interactions involve the use of over-the-counter medications, such as aspirin or dietary supplements. According to the study, one in 25 older adults are at risk for serious drug interactions, the study has found. And for men ages 75 and 85, the risk is as high as 1 and 10. 